Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Evaluating the effects of venetoclax and obinutuzumab in patients with untreated chronic lymphocytic leukemia

Posted by on Feb 11, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the treatment benefits of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The main finding was that the combination therapy improved outcomes in these patients. Some background Most patients with CLL are older...

Read More

The risks of invasive fungal infections in patients treated with venetoclax and hypomethylating agents for acute myeloid leukemia

Posted by on Feb 3, 2020 in Leukemia | 0 comments

In a nutshell The study examined the risks of invasive fungal infections (IFIs) in patients with acute myeloid leukemia (AML), who were treated with venetoclax (Venclexta) and hypomethylating agents (VEN-HMAs). The authors found that the occurrence of IFIs was low during VEN-HMA treatment. Some background Venetoclax is a targeted therapy. It blocks...

Read More

Premedication with methylprednisolone before obinutuzumab treatment in patients with chronic lymphocytic leukemia

Posted by on Jan 30, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if pretreatment with methylprednisolone would reduce infusion-related reactions associated with obinutuzumab use in patients with chronic lymphocytic leukemia.   This study concluded that premedication with methylprednisolone reduces infusion-related reactions...

Read More

Comparing time to next treatment, health care resource utilization and costs between patients with chronic lymphocytic treated with ibrutinib or chemoimmunotherapy

Posted by on Jan 27, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to compare health care costs, resource utilization and time to the next treatment in patients with chronic lymphocytic leukemia who received ibrutinib or chemoimmunotherapy.  This study concluded that ibrutinib in these patients was associated with lower medical costs and longer time...

Read More

Factors associated with patient-reported symptoms in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Posted by on Jan 25, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate which factors are associated with patient-reported symptoms and their impact on quality-of-life in patients with chronic myeloid leukemia who are receiving tyrosine kinase inhibitors.  This study concluded that there were a number of factors associated with patient-reported symptoms in these...

Read More

Is asparaginase-associated pancreatitis dependent on the age of patients with acute lymphoblastic leukemia?

Posted by on Jan 21, 2020 in Leukemia | 0 comments

In a nutshell This study evaluated whether the risk and severity of asparaginase-associated pancreatitis (AAP) depend on the age of patients with acute lymphoblastic leukemia (ALL). The main finding was that the AAP risk was higher in adolescents and adults compared to younger children. Some background Asparaginase (ASP; Oncaspar) is an important...

Read More

Evaluating acalabrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia

Posted by on Jan 21, 2020 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL). The authors concluded that this combination was effective and well tolerated in patients with CLL. Some background Chronic lymphocytic leukemia (CLL) is a cancer...

Read More